Scientists are rapidly investigating retatrutide, a novel treatment from Eli Lilly, as a potential step in body management. Unlike many existing approaches, retatrutide is a dual -action receptor targeting both GLP-1 and GIP, hormones that influence hunger and blood sugar regulation . Early rese